Skip to main content

1243 results

Publication

VETOQUINOL RECEIVES FDA APPROVAL FOR FELPREVA™ IN THE USA

Vetoquinol announces that Felpreva™ received approval from the U.S. Food & Drug Administration (FDA). Felpreva™ is a broad‑spectrum parasiticide designed specifically for cats which is applied just four times a year in a topical dose.
Publication

Monthly information regarding the total number of voting rights – october 2026

As per articles L233‐8‐II of « Code de Commerce » and 223.16 of the «Reglement Général de L’Autorité des Marchés Financiers »
Publication

Buyback programs - October 2026

Monthly communication regarding buyback programs
Publication

Sales at end September 2026

9-months sales: €399 million (+5.4% at constant exchange rates and +3.9% on a reported basis) 9-month sales of Essential Products: €259 million (+6.0% at constant exchange rates and +6.7% on a reported basis)
Publication

Monthly information regarding the total number of voting rights – september 2026

As per articles L233‐8‐II of « Code de Commerce » and 223.16 of the «Reglement Général de L’Autorité des Marchés Financiers »
Publication

Buyback programs - September 2026

Monthly communication regarding buyback programs
Publication

2026 Half-Year Results

Contents: 01. Activity for the first half of 2026 02. Consolidated results as of June 30, 2026 03. Strategy and outlook
Publication

2026 Half-Year Results

Sales: €259 million (+3.4% at constant exchange rates and +0.7% on a reported basis) Essential Products sales: €169 million (+3.7% at constant exchange rates and +2.2% on a reported basis) EBIT before AAA: €45 million (17.3% of sales) Net income, Group share: €30 million (11.8% of sales) Cash flow...
Publication

Monthly information regarding the total number of voting rights – August 2026

As per articles L233‐8‐II of « Code de Commerce » and 223.16 of the «Reglement Général de L’Autorité des Marchés Financiers »
Publication

Buyback programs - August 2026

Monthly communication regarding buyback programs